Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > If 2021 is any indication ...

<< Previous

Bullboard Posts

Next >>

Comment by davgroon Jun 24, 2022 9:18pm

131 Views

Post# 34781822

RE:If 2021 is any indication ...

The following is an excerpt from today's Thomson Reuters StockReports+ for ATE. They have listed the next expected report date as June 29th, 2022.

MrMugsy wrote: Going into the last week of June !

It was on the last Monday of June 2021 that we received the financials and an update.
It never seems to work out the same ... but ... conditions are similar in 2022 as they were in 2021 - no financing news - no other news getting in the way - so - I'm betting on a repeat for financials in the final week of June.

Good thing I'm not putting any cash on that one.

Add to that to the comments made at Bloom Burton and the timing seems "about" right.

Have a good weekend Longs !